Causal Assessment of Serum Urate Levels in Cardiometabolic Diseases Through a Mendelian Randomization Study



Tanya Keenan, MD, MPH,^{a,b} Wei Zhao, MSc,^a Asif Rasheed, MBBS,^c Weang K. Ho, PHD,^d Rainer Malik, PHD,^e Janine F. Felix, PHD,^f Robin Young, PHD,^d Nabi Shah, PHD,^c Maria Samuel, MSc,^c Nasir Sheikh, MSc,^d Megan L. Mucksavage, MSc,^a Omar Shah, MD,^a Jin Li, PHD,^g Michael Morley, PHD,^h Annika Laser, MSc,^{i,j} Nadeem Hayat Mallick, MBBS,^k Khan Shah Zaman, MBBS,¹ Mohammad Ishaq, MBBS,^m Syed Zahed Rasheed, MD,^m Fazal-ur-Rehman Memon, MBBS,ⁿ Faisal Ahmed, MBBS,^o Bashir Hanif, MD,^p Muhammad Shakir Lakhani, MBBS,^p Muhammad Fahim, MBBS,^c Madiha Ishaq, MBBS,^c Naresh Kumar Shardha, MBBS,^c Naveeduddin Ahmed, MBBS,^q Khalid Mahmood, MBBS,^r Waseem Iqbal, MBBS,^s Saba Akhtar, MBBS,^c Rabia Raheel, MBBS,^c Christopher J. O'Donnell, MD, MPH,^{t,u,v} Christian Hengstenberg, MD,^w Winifred März, MD,^{x,y,z} Sekar Kathiresan, MD,^{u,v,aa,bb} Nilesh Samani, MD,^{cc} Anuj Goel, PHD,^{dd} Jemma C. Hopewell, PHD,^{ee} John Chambers, PHD,^{ff} Yu-Ching Cheng, PHD,^{gg} Pankaj Sharma, MD, PHD,^{hh} Qiong Yang, MD,ⁱⁱ Jonathan Rosand, MD,^{jj} Giorgio B. Boncoraglio, MD,^{kk} Shahana Urooj Kazmi, PHD,^l Hakon Hakonarson, PHD,^g Anna Köttgen, MD, MPH,^{mm,mn} Andreas Kalogeropoulos, MD,^{oo} Philippe Frossard, PHD,^c Ayeesha Kamal, MD,^{pp} Martin Dichgans, MD,^e Thomas Cappola, MD,^{qq} Muredach P. Reilly, MBBCH, MSCE,^{a,qq} John Danesh, DPHE,^d Daniel J. Rader, MD,^a Benjamin F. Voight, PHD,^{rr} Danish Saleheen, PHD^{a,c,ss}

ABSTRACT

BACKGROUND Although epidemiological studies have reported positive associations between circulating urate levels and cardiometabolic diseases, causality remains uncertain.

OBJECTIVES Through a Mendelian randomization approach, we assessed whether serum urate levels are causally relevant in type 2 diabetes mellitus (T2DM), coronary heart disease (CHD), ischemic stroke, and heart failure (HF).

METHODS This study investigated 28 single nucleotide polymorphisms known to regulate serum urate levels in association with various vascular and nonvascular risk factors to assess pleiotropy. To limit genetic confounding, 14 single nucleotide polymorphisms exclusively associated with serum urate levels were used in a genetic risk score to assess associations with the following cardiometabolic diseases (cases/controls): T2DM (26,488/83,964), CHD (54,501/68,275), ischemic stroke (14,779/67,312), and HF (4,526/18,400). As a positive control, this study also investigated our genetic instrument in 3,151 gout cases and 68,350 controls.

RESULTS Serum urate levels, increased by 1 SD due to the genetic score, were not associated with T2DM, CHD, ischemic stroke, or HF. These results were in contrast with previous prospective studies that did observe increased risks of these 4 cardiometabolic diseases for an equivalent increase in circulating urate levels. However, a 1 SD increase in serum urate levels due to the genetic score was associated with increased risk of gout (odds ratio: 5.84; 95% confidence interval: 4.56 to 7.49), which was directionally consistent with previous observations.

CONCLUSIONS Evidence from this study does not support a causal role of circulating serum urate levels in T2DM, CHD, ischemic stroke, or HF. Decreasing serum urate levels may not translate into risk reductions for cardiometabolic conditions. (J Am Coll Cardiol 2016;67:407-16) © 2016 by the American College of Cardiology Foundation.

Listen to this manuscript's audio summary by *JACC* Editor-in-Chief Dr. Valentin Fuster.



From ^aTranslational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; ^bDepartment of Medicine, Massachusetts General Hospital, Boston, Massachusetts; ^cCenter for Non-Communicable Diseases, Karachi, Pakistan; ^dDepartment of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; ^eLudwig-Maximilians-University Munich, Medical Center, Institute for Stroke and Dementia Research (ISD), Munich,

ABBREVIATIONS AND ACRONYMS

CHD = coronary heart disease

GRS = genetic risk score HF = heart failure

- MR = Mendelian randomization

SNP = single nucleotide polymorphism

T2DM = type 2 diabetes mellitus ric acid is the end product of purine metabolism and circulates in the blood as the anion urate. Blood levels of uric acid are causally associated with gout, as implicated by evidence from randomized clinical trials using urate-lowering therapies (1). In 1923, Kylin initially described a constellation of metabolic disturbances that included hypertension, hyperglycemia, and elevated uric acid levels. Since then, circulating levels of serum uric acid have been reported to be positively correlated

In 1923, Kylin initially (4-7), ischemic stroke (8,9), and heart failure on of metabolic disturhypertension, hyperred, wright agrid lowels

> No large-scale intervention studies, however, have evaluated urate-lowering therapies for metabolic and

> with several vascular risk factors including blood

pressure, lipids, kidney function, and other metabolic

traits (2). A number of prospective epidemio-

logical studies have associated increased serum

uric acid levels and elevated risk for type 2 diabetes

mellitus (T2DM) (3), coronary heart disease (CHD)

Germany; ^fDepartment of Epidemiology, Erasmus MC University Medical Center Rotterdam, the Netherlands and The Netherlands Genomics Initiative, Netherlands Consortium for Healthy Aging (NGI-NCHA), Leiden, the Netherlands; ^gChildren's Hospital of Philadelphia, Philadelphia, Pennsylvania; hDepartment of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; ⁱResearch Unit of Molecular Epidemiology, Helmholtz Zentrum München, Neuherberg, Germany; ⁱInstitute of Epidemiology II, Helmholtz Zentrum München, Neuherberg, Germany; ^kPunjab Institute of Cardiology, Lahore, Pakistan; ^lNational Institute of Cardiovascular Diseases, Karachi, Pakistan; "Karachi Institute of Heart Diseases, Karachi, Pakistan; "Red Crescent Institute of Cardiology, Hyderabad, Pakistan; ^oDepartment of Cardiology, Liaquat National Hospital, Karachi, Pakistan; ^pDepartment of Cardiology, Tabba Heart Institute, Karachi, Pakistan; ^qDepartment of Neurology, Liaquat National Hospital, Karachi, Pakistan; ^rDepartment of Medicine, Dow University of Health Sciences, Civil Hospital, Karachi, Pakistan: ^sDepartment of Medicine, Lahore General Hospital, Lahore, Pakistan; ¹National Heart, Lung, and Blood Institute Framingham Heart Study, Framingham, Massachusetts; ^uCardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts; ^vDepartment of Medicine, Harvard Medical School, Boston, Massachusetts; "Internal Medicine II - Cardiology, University Hospital of Regensburg, Regensburg, Germany; *Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria; ^yMedical Clinic V, Mannheim Medical Faculty, University of Heidelberg, Mannheim, Germany; ^zSynlab Academy, Synlab Laboratory Services GmbH, Mannheim, Germany; ^{aa}Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts; bbProgram in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts; ccDepartment of Cardiovascular Sciences, University of Leicester, Clinical Sciences Wing, Glenfield General Hospital, Leicester, United Kingdom; ^{dd}Wellcome Trust Center for Human Genetics, University of Oxford, Oxford, United Kingdom; ^{ee}Division of Cardiovascular Science, Oxford University, Oxford, United Kingdom; ffSchool of Public Health, Imperial College, London, United Kingdom; ggDepartment of Medicine, University of Maryland School of Medicine, Baltimore VA Medical Center, Baltimore, Maryland; hh Imperial College London & Hammersmith Hospitals, London, United Kingdom; ⁱⁱSchool of Public Health, Boston University, Boston, Massachusetts; ⁱⁱDivision of Neurocritical Care, Massachusetts General Hospital, Boston, Massachusetts; ^{kk}Department of Cerebrovascular Diseases, Fondazione IRCCS Istituto Neurologico, Milan, Italy; ¹¹Department of Microbiology, University of Karachi, Karachi, Pakistan; mmRenal Division, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany; nnDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; ooDivision of Cardiology, School of Medicine, Emory University, Atlanta, Georgia; ppDivision of Neurology, Department of Medicine, Aga Khan University, Karachi, Pakistan: ^{qq}Cardiovascular Division, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; ^{II}Department of Systems Pharmacology and Translational Therapeutics and Department of Genetics, University of Pennsylvania, Philadelphia, Pennsylvania; and the ^{ss}Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania. Dr. Saleheen has received funding from the National Institutes of Health, the Fogarty International, the Wellcome Trust, the British Heart Foundation and Pfizer. Dr. Voight was supported by a Fellowship from the Alfred P. Sloan Foundation (BR2012-087), and has received funding from the American Heart Association (13SDG14330006), and the W.W. Smith Charitable Trust (H1201). Acknowledgments by studies that contributed data to the analyses are as follows: PROMIS and RACE. Dr. Saleheen is the PI of the PROMIS and RACE studies. Genotyping in PROMIS was funded by the Wellcome Trust, UK and Pfizer. Biomarker assays in PROMIS have been funded through grants awarded by the NIH (RC2HL101834 and RC1TW008485) and the Fogarty International (RC1TW008485). The RACE study has been funded by the National Institute of Neurological Disorders (R21NS064908), the Fogarty International (R21NS064908), and the Center for Non-Communicable Diseases, Karachi, Pakistan. Dr. Kathiresian has received research grants from Regeneron, Bayer, and Aegerion; is a consultant with Novartis, Aegerion, Bristol-Myers Squibb, Sanofi, AstraZeneca, Alhylam, Lilly, Leerink Partners, Merck, and Noble Insights; has received SAB from Catabasis, Regeneron Genetics Center, Merck, and Celera; and has equity with San Therapeutics and Catabasis. Dr. Thomas is a DSMB member with Novartis; and has received lab assays from BG Medicine. Dr. Danesh is a consultant with Takeda; a member of the Novartis Cardiovascular & Metabolic Advisory Board; a member of the International Cardiovascular and Metabolism Research and Development portfolio committee at Novartis; a member of the Merck Sharp & Dohme UK Atherosclerosis Advisory Board; a member of Sanofi Advisory Board; and has received funding from the British Heart Foundation, BUPA Foundation, diaDexus, European Research Council, European Union, Evelyn Trust, Fogarty International Centre, GlaxoSmithKline, Merck, National Heart, Lung, and Blood Institute, National Health Service Blood and Transplant, National Institute for Health Research, National Institute of Neurological Disorders and Stroke, Novartis, Pfizer, Roche, Sanofi, Takeda, The Wellcome Trust, UK Biobank, University of British Columbia, and the UK Medical Research Council. Studies participating in the METASTROKE consortium: The MGH Genes Affecting Stroke Risk and Outcome Study (MGH-GASROS). GASROS was supported by the National Institute of

vascular outcomes. In the absence of such evidence, it remains unknown whether circulating uric acid is an independent causal factor for cardiometabolic conditions and whether lowering urate levels might offer therapeutic utility in these disorders.

Human genetic data can be used to directly test the hypothesis of causality between uric acid and clinical endpoints. In particular, Mendelian randomization (MR) studies assess causal inference by using genetic alleles as unbiased proxies for circulating biomarkers (12). MR studies are based on the random assortment of genetic alleles during meiosis that can confer advantages similar to a randomized controlled trial by investigating the relationship between genetic alleles that are exclusively associated with a biomarker of interest and disease risk (13). Previously, such an approach has been used to assess the causality of low- and high-density lipoprotein cholesterol (14), triglycerides (15), lipoprotein(a) (16,17), fibrinogen (18), and C-reactive protein in CHD (19).

This study's objective is to test the hypothesis that serum urate levels are causally associated with cardiometabolic conditions by applying an MR study design. We integrated information on genetic variants related to serum urate, 50 potential confounders, and risk of disease outcomes. In contrast to previously published genetic reports on serum urate–related genetic variants and disease risk (20-23), the current study investigates >10 times more CHD cases and examines, for the first time, risks of stroke and HF conferred by genetically raised serum urate levels. It also systematically evaluates pleiotropy, enabling reliable assessment of any possible moderate causal effect of serum urate levels on any of the 4 major cardiometabolic outcomes.

METHODS

STUDY DESIGN. Our study had 3 interrelated components. First, we selected single nucleotide polymorphisms (SNPs) previously discovered in genome-wide association studies of serum urate levels. Second, we conducted genetic analyses in relation to a panel of 50 vascular and nonvascular risk factors and identified SNPs that did not exhibit pleiotropy (i.e., SNPs exclusively associated with circulating urate levels, but not with other cardiometabolic traits that might confound our interpretation). For these analyses, we queried publicly available resources and genome-wide association data available from 18,828 subjects of PROMIS (Pakistan Risk of Myocardial Infarction Study), a case-control study in urban Pakistan (24). Third, we used a genetic risk score (GRS) comprised of SNPs exclusively associated with serum urate levels to evaluate the potential causal role of circulating urate levels in T2DM, CHD, ischemic stroke, and HF through an MR approach.

URATE GENETIC VARIANTS AND ASSESSMENT OF PLEIOTROPY. All of the 28 urate SNPs included in the current analyses were in linkage equilibrium ($r^2 = 0$, based on participants of European, South Asian, and East Asian ancestries in the International HapMap Project phase II and phase III) (25). Each SNP was evaluated for associations with 50 vascular and nonvascular traits in up to 18,828 PROMIS participants (24). Information from publicly available genome-wide associations studies databases was also used to assess associations of these SNPs with blood pressure traits in up to 134,433 participants (Global BPgen Consortium) (26); with major lipids in up to 100,000 participants (Global Lipids Genetics

Neurological Disorders and Stroke (U01 NS069208), the American Heart Association/Bugher Foundation Centers for Stroke Prevention Research 0775010N, the National Institutes of Health and National Heart, Lung, and Blood Institute's STAMPEED genomics research program (R01 HL087676), and a grant from the National Center for Research Resources. The Broad Institute Center for Genotyping and Analysis is supported by grant U54 RR020278 from the National Center for Research resources. CHARGE-Stroke data. This work was supported by the dedication of the Framingham Heart Study participants, the National Heart, Lung, and Blood Institute's Framingham Heart Study (Contract No. N01-HC-25195), and by grants from the National Institute of Neurological Disorders and Stroke (NS17950), the National Institute of Aging (AG033193), the and the National Heart, Lung, and Blood Association (HL93029, U01HL 096917). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke, the National Heart, Lung, and Blood Institute, the National Institute of Aging, or the National Institutes of Health. BRAINS. Pankaj Sharma is supported by a Department of Health (UK) Senior Fellowship. BRAINS is supported by grants from British Council (UK-India Education and Research Initiative), Henry Smith Charity, and Qatar National Research Fund. Funding support for GEOS was provided by NIH grants U01-HG004436 and U01-NS069208. CHARGE Heart Failure Consortium. At the time of preparation of the manuscript, Janine F Felix was working in Erasmus AGE, a center for aging research across the life course funded by Nestlé Nutrition (Nestec Ltd.), Metagenics Inc., and AXA. These funding sources had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review or approval of the manuscript. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Dr. Keenan and Mr. Zhao are joint first authors. Dr. Voight and Dr. Saleheen are joint senior authors.

Consortium) (27), with anthropometric traits in up to 183,727 participants (Genetic Investigation of ANthropometric Traits) (28-30); and with glycemic traits in up to 46,368 nondiabetic participants (Meta-Analyses of Glucose and Insulin-related traits Consortium) (31-34). Pleiotropy was declared at a nominal p value of <0.01. Only nonpleiotropic SNPs were used to construct a urate-specific GRS. We used additive linear regression models to interrogate the urate GRS in association with a range of traits in PROMIS.

ASSOCIATION WITH DISEASE OUTCOMES. For each of the 28 SNPs, summary effect estimates in association with T2DM, CHD, ischemic stroke, and HF were obtained from various consortia, including DIAGRAM (DIAbetes Genetics Replication And Meta-analysis consortium) (35), CARDIoGRAM (Coronary ARtery DIsease Genome-wide Replication and Meta-analysis consortium) (36), C4D (Coronary Artery Disease Genetics consortium) (36), METASTROKE (META-STROKE Collaboration) (37), and CHARGE-Heart Failure studies (Cohorts for Heart and Aging Research in Genomic Epidemiology consortium) (38). DIAGRAM data were downloaded from their website; other data were acquired by contacting investigators within each consortium. We maximized study power by obtaining further data on participants who did not contribute to any of these consortia previously, thus increasing sample size for CHD, ischemic stroke, and HF by up to 25% (Online Table 1). Effect sizes and errors from consortia data and study-specific effect sizes and errors from additional studies (Online Table 1) were combined via meta-analysis (inverse-variance fixed-effect model). In the final analyses, data were available on 26,488 T2DM cases and 83,964 controls; 54,501 CHD cases and 68,275 controls; 14,779 ischemic stroke cases and 67,312 controls; and 4,553 HF cases and 19,985 controls. Effect estimates in association with prevalent gout were obtained from GUGC (Global Urate Genetics Consortium) involving 3,151 gout cases and 68,350 controls (39). All participants were of self-reported European or South Asian ancestry. Individual studies within each consortium obtained written informed consent from participants and received approval from the relevant ethics boards.

STATISTICAL ANALYSES. All 28 SNPs used in the current analyses have been previously shown to be associated with serum urate levels at a p value of $<5 \times 10^{-8}$ (39). The association of each SNP with each cardiometabolic outcome was evaluated with a fixed-effects, inverse-variance, weighted meta-analysis using beta(s) and SE(s) obtained from consortia and studies listed in Online Table 1. SNPs found exclusively associated with serum urate levels

were used in a genetic score as an instrument for MR analyses (39,40). The impact of the urate genetic score on disease risk was calculated using methods described previously (41,42). Briefly, under the assumptions that SNPs are unlinked and the effects of each SNP are log additive on uric acid levels, using an MR framework (12,13), a causal effect (alpha) between a biomarker and outcome can be estimated by

$$\alpha \, = \, \Big({\sum}_{j} \beta w s^{-2} \Big) \Big/ \Big({\sum}_{j} w^2 s^{-2} \Big)$$

where for all j SNPs, β represents the estimated natural log odds effect of the *j*-th SNP on the endpoint of interest, s represents the standard error on the log odds effect of the *j*-th SNP on the endpoint, and w represents a weight for the SNP on the outcome. Each SNP was weighted using the reported estimated effect of the SNP on uric acid levels (in SD units). SE for alpha-hat was calculated by taking the square root of the reciprocal of the denominator, as previously described (42). A simulation approach was used to estimate the power to identify or exclude causal effects of the urate genetic score on each tested outcome (Online Appendix) (43). All analyses were conducted in STATA (StataCorp LP, College Station, Texas), R (The R Foundation), SNPTEST (University of Oxford), or PLINK (Harvard University).

RESULTS

URATE VARIANTS. Of the 28 SNPs related to serum urate levels, 14 variants had pleiotropic associations at a p value <0.01 with at least 1 vascular or nonvascular trait (Online Tables 2 and 3). The remaining 14 nonpleiotropic SNPs were used in a genetic score weighted for the reported urate effect estimate of each SNP. The weighted GRS was not associated with any vascular or nonvascular trait at a p value <0.01 (Figure 1).

Of the 14 urate-specific SNPs, 9 variants were associated with increased risks of gout but none of the variants were associated with T2DM, CHD, ischemic stroke, or HF at a p value <0.01 (Figures 2 and 3). Most notably, the SNP at the SLC2A9 locus, which was associated with the largest increases in serum urate level (0.37 mg/dl) and risk of gout (odds ratio [OR]: 1.56; 95% confidence interval [CI]: 1.45 to 1.68; $p = 1.9 \times$ 10⁻³¹), was not associated with any of the cardiometabolic outcomes. Of the 14 pleiotropic SNPs, we found 1 SNP at the ATXN2 locus to be significantly associated with increased risk of CHD (OR: 1.06; 95% CI: 1.03 to 1.08; $p = 6.5 \times 10^{-6}$) and ischemic stroke (OR: 1.08; 95% CI: 1.04 to 1.11; $p = 4.4 \times 10^{-6}$) (Online Table 4). The variant at the VEGFA locus was significantly associated with decreased risk of T2DM

FIGURE 1 Association of Urate Genetic Score With Pote	ntial Confounders		
Trait	Ν		P-value
Total Cholesterol	18828		0.55
Log-Triglycerides	18731	_ _	0.35
Glucose	18107		0.63
High-Density Lipoprotein Cholesterol	18259	·	0.34
Low-Density Lipoprotein Cholesterol	18595		0.34
Systolic Blood Pressure	18452		0.78
Diastolic Blood Pressure	18266		0.34
Heart Rate	18526		0.97
Waist Circumference	18209		0.31
Hip Circumference	18200		0.10
Weight	18104		0.09
Height	18226		0.12
Hemoglobin A1c	13656		0.65
LpPLA2 Mass	11021		0.66
LpPLA2 Activity	12054		0.35
Apolipoprotein A1	12054		0.33
Apolipoprotein B	12114		0.25
Log Lipoprotein(a)	12118	<u> </u>	0.25
Estimated Glomerular Filtration Rate	10055		0.30
Body Mass Index	18013		0.30
Waist to Hip Ratio	18197		0.27
Apolipoprotein C3	12033		0.22
Non-Esterified Fatty Acids	12126		0.65
Apolipoprotein E	12128		0.33
Apolipoprotein A2	12128		0.33
Apolipoprotein A5	10679	·	0.34
Angiopoietin-like Protein 3	10137		0.54
Chemokine (CXC Motif) Ligand 12	9092		0.72
Fibroblast Growth Factor 21	9156		0.13
E-selectin	8324	· · · · · · · · · · · · · · · · · · ·	0.43
Angiopoietin-like Protein 4	9281		0.99
C-peptide	9660		0.62
Matrix Metallopeptidase 9	8523		0.30
Insulin	8444		0.06
Oxidized Phospholipids/Apolipoprotein B	6783		0.27
P-selectin	5798		0.30
Intracellular Adhesion Molecule	5758		0.50
Vascular Cell Adhesion Molecule	5721	_	0.69
Cystatin C	4951		0.74
Log-C-Reactive Protein	4485	_	0.42
CD-40 Ligand	3801		0.22
Eotaxin	3767		0.06
Factor-VII	3846		0.95
Interleukin 8	3771	_	0.36
Matrix Metallopeptidase 3	3796		0.52
Superoxide Dismutase	3846		0.56
Thrombomodulin	3845		0.86
Vascular Endothelial Growth Factor	3846		0.27
		25 0 .25	
		Per SD Change	
Of the 28 single nucleotide polymorphisms (SNDc) related t	o serum urate levels 14	variants had pleiotropic associations	at a $p < 0.01$ with at

Of the 28 single nucleotide polymorphisms (SNPs) related to serum urate levels, 14 variants had pleiotropic associations at a p < 0.01 with at least 1 vascular or nonvascular trait. The remaining 14 nonpleiotropic SNPs were used to calculate a genetic score by using individual participant data in the PROMIS (Pakistan Risk of Myocardial Infarction Study) participants. The genetic score was weighted for the reported urate effect estimate of each SNP. The genetic score was subsequently used in analyses with 50 traits in the PROMIS participants and was not found associated with any trait at a p < 0.01. LpPLA2 = lipoprotein-associated phospholipase A2.

(OR: 0.93; 95% CI: 0.89 to 0.96; $p = 1.0 \times 10^{-4}$) but increased serum urate levels (Online Table 5).

URATE GENETIC SCORE AND DISEASE OUTCOMES. For a 1 SD increase in serum uric acid levels, the OR of gout conferred by genetic score was 5.84 (95% CI: 4.56 to 7.49; $p = 4.2 \times 10^{-44}$), which was directionally consistent with the observed OR of 2.12 (95% CI: 1.90 to 2.33) for gout in epidemiological studies (44). However, a 1 SD increase in serum urate due to the genetic score had no relationship with T2DM

FIGURE 2 Urate	Variants:	Association	FIGURE 2 Urate Variants: Associations With Serum Urate, Gout, and Diabetes	and Dia	betes								
SNP	Gene	A1(F1)/A2*		∆ Urate	A Urate* p value*	-	Gout O	Gout OR* p value*		Cases/Controls	T2D OR	95% CI	p value
rs17786744	STC1	G(0.42)/A	•	0.029	0.029 1.40E-08	ł	1.08	0.21		26488/83964	0.99	(0.97,1.02)	0.70
rs7976059	ACVR1B-L1	ACVR1B-L1 T(0.35)/G	+	0.032	1.90E-09		0.95	0.18		26488/83964	1.00	(0.97,1.03)	0.95
rs10480300	PRKAG2	T(0.28)/C	•	0.035	4.10E-09	ł	1.09	6.5E-03		26488/83964	0.99	(0.95,1.03)	0.53
rs17632159	TMEM171		•	0.039	3.50E-11	ł	1.10	6.0E-03		26488/83964	1.02	(0.99,1.05)	0.24
rs7224610	HLF	C(0.42)/A	•	0.042	5.40E-17		1.04	0.16	-	26488/83964	1.01	(0.99,1.04)	0.34
rs2941484	HNF4G	T(0.44)/C	•	0.044	4.40E-17		1.04	0.17		26488/83964	1.01	(0.99,1.04)	0.65
rs6770152	SFMBT1	G(0.42)/T	+	0.044	2.60E-16	ł	11.11	3.0E-04		26488/83964	1.00	(0.98,1.03)	0.72
rs478607	NRXN2	G(0.16)/A	+	0.047	4.40E-11		1.03	0.41		26488/83964	0.99	(0.96,1.03)	0.71
rs11264341	TRIM46	C(0.57)/T	+	0.050	6.20E-19	+	1.09	7.4E-03	•-+-	26488/83964	0.98	(0.95,1.01)	0.28
rs10821905	A1CF	A(0.18)/G	ŧ	0.057	7.40E-17		1.09	0.03		26488/83964	1.03	(0.1,00)	0.11
rs1471633	PDZK1	A(0.46)/C		0.059	1.20E-29		1.03	0.28		26488/83964	1.01	(0.98,1.04)	0.41
rs675209	RREB1	T(0.27)/C	+	0.061	1.30E-23	+	1.09	0.01		26488/83964	1.02	(0.99,1.05)	0.26
rs2078267	SLC22A11	C(0.49)/T	+	0.073	9.40E-38	+	1.14	2.3E-05	1	26488/83964	0.98	(0.96,1.00)	0.08
rs12498742	SLC2A9	A(0.77)/G	•	0.373	<1.0E-700		1.56	1.9E-31	-+	26488/83964	0.98	(0.95,1.01)	0.29
		ō	0.0 0.1 0.2 0.3 0.4	4	Ğ	0.9 1.0	1.7		0.1 0.1	_ =			
			Δ Urate (mg/dl) *			Gout OR (95% CI)*	*(1		Type 2 Diabetes OR (95% CI)	(1			
					-		-		-	-		-	
Of the 14 urate-sp	ecific SNPs	investigated	Of the 14 urate-specific SNPs investigated in association with serum urate, gout, and type 2 diabetes mellitus (12DM), only 9 variants were found associated with increased risks of gout but none were found associated with	rate, gou	t, and type 2 (diabetes mellitus (12D	M), only 9 var	iants were foi	und associated with increa:	sed risks of gout bu	t none we	re tound asso	clated with

T2DM at a p < 0.01. *Data presented from a serum urate genome-wide association study of 48 studies (n = 110, 247) and a gout meta-analysis of 14 studies (3,151 cases, 68,350 controls) (39). A1 = modeled allele; A2

OR = odds ratio; other abbreviations as in Figure 1

of modeled allele;

= frequency

Ē

nonmodeled allele; CI = confidence interval;

(OR: 0.95; 95% CI: 0.86 to 1.05; p = 0.28), CHD (OR: 1.02; 95% CI: 0.92 to 1.12; p = 0.73), ischemic stroke (OR: 0.99; 95% CI: 0.88 to 1.12; p = 0.93), or HF (OR: 1.07; 95% CI: 0.88 to 1.30; p = 0.51) (Central Illustration). In further subsidiary analysis, a GRS comprised of all 28 urate-related SNPs was not associated with the 4 cardiometabolic outcomes (Online Table 6). A score based on the 14 urate-related variants with pleiotropic effects was also not associated with stroke or HF (Online Table 7). However, this score was nominally associated with T2DM, though in a direction opposite of epidemiological expectation, and weakly associated with CHD. We posit that these weak associations are explained by strong, confounding associations of these SNPs with blood pressure, cholesterol, triglycerides, obesity, glucose, insulin, and insulin resistance (Online Table 3). These null associations are in contrast to data from observational epidemiological studies which have previously shown that equivalent increases in serum urate levels are associated with increased risks of T2DM (OR: 1.25; 95% CI: 1.13 to 1.37) (3), CHD (OR: 1.06; 95% CI: 1.03 to 1.09) (4), ischemic stroke (OR: 1.17; 95% CI: 1.00 to 1.37) (8), and HF (OR: 1.19; 95% CI: 1.17 to 1.21) (10).

For a 1 SD change in serum urate levels due to genetic score, our study was statistically powered at >80% with a 5% alpha rate to assess ORs of 1.15 for T2DM, 1.17 for ischemic stroke, 1.10 for CHD, and 1.24 for HF.

We conducted sensitivity analyses and investigated, in the same study population, the associations of the previously published urate-related SNPs with serum urate levels and CHD risk. In the 7 studies analyzed, we found highly significant associations for uric acid levels by the 3 risk scores that we used in the main analyses earlier (Online Figure 1A) whereas no association was observed between any of the risk scores investigated and CHD risk in the same studies (Online Figure 1B). We further restricted our analyses to 3 studies in which we investigated the association of: 1) serum urate levels with CHD risk; 2) SNPs with serum urate levels; and 3) SNPs with CHD risk. Although we found highly significant associations between circulating serum urate levels and CHD risk (Online Figure 2A) and highly significant associations between SNPs and serum urate levels (Online Figure 2B), no association was observed for any of 3 urate-related GRSs with CHD risk (Online Figure 2C). These sensitivity analyses provide further validation to the "2-stage" MR experiment used earlier. Further, in analyses stratified by ethnicity, similar null results were obtained for participants of European or South Asian origin (Online Tables 8 to 10).

412

Contrary to epidemiological studies in humans in which higher serum urate levels correlate with increased risk of cardiometabolic outcomes, the MR analyses reported here provided no evidence of causal associations between circulating urate levels and risks of T2DM, CHD, ischemic stroke, or HF (Central Illustration). First, we analyzed all SNPs associated with circulating urate levels across a range of vascular and nonvascular traits to assess pleiotropy, and identified 14 exclusively associated with serum urate levels. Second, a genetic score combining these nonpleiotropic variants exclusively increased uric acid levels and risk of gout. Third, none of the urate-specific SNPs individually or combined as a genetic score associated with any cardiometabolic outcome. Fourth, a genetic risk score comprised of all 28 SNPs known to regulate serum urate levels was not associated with any cardiometabolic outcome.

The current study raised doubts about the etiological relevance of serum uric acid in cardiovascular and metabolic diseases as suggested by prior epidemiological and model systems studies (3-11,45), which may have observed increased uric acid levels to associate with higher risk of cardiometabolic diseases due to residual confounding or reverse causality. Moreover, no large-scale randomized control trials have been conducted using targeted interventions to lower serum urate levels (e.g., xanthine-oxidase inhibition inhibition) for the primary prevention of cardiometabolic endpoints, although an ongoing trial is evaluating the role of xanthine-oxidase inhibitors in patients with HF (46). Prior studies have suggested a role for urate-lowering therapies in reducing blood pressure in adolescents with hyperuricemia, ameliorating exercise capacity in patients with chronic stable angina, improving endothelial function in patients with HF, and making other biochemical parameters more favorable in patients with stable disease (47-49). Such evidence, however, was generated through studies conducted in populations with prevalent and stable disease and did not assess the association of urate reduction with primary cardiometabolic events (i.e., stroke, CHD, diabetes, or HF). Moreover, these prior studies do not address the etiological relevance of urate reduction in the prevention of primary cardiometabolic events in healthy participants. In contrast, findings from this report suggested that uric acid lowering may not succeed in primary prevention of metabolic and vascular events, consistent with a recent study that showed initiation of xanthine oxide inhibitors in patients with gout was not associated with a change in cardiovascular disease risk (50).

FIGURE 3 Urate Variants: Associations With Coronary Heart Disease, Ischemic Stroke, and Heart Failure

																	 <u> </u>		
p value	0.76	0.35	0.49	0.34	0.28	0.72	0.39	0.36	0.46	0.48	0.65	0.75	0.27	0.67				ed from	
95% CI	(0.93, 1.05)	(0.92, 1.03)	(0.96, 1.09)	(0.87, 0.99)	(0.98, 1.09)	(0.93, 1.05)	(0.92, 1.03)	(0.89, 1.04)	(0.96, 1.09)	(0.85, 1.00)	(0.96, 1.07)	(0.95, 1.08)	(0.98, 1.09)	(0.92, 1.06)				ata preseni	
HF OR	0.99	0.97	1.02	0.93	1.03	0.99	0.98	0.96	1.02	0.92	1.01	1.01	1.03	66.0				0.01. *D	
Cases/Controls	2526/18400	2526/18400	2526/18400	2526/18400	2526/18400	2526/18400	2526/18400	2526/18400	2526/18400	2526/18400	2526/18400	2526/18400	2526/18400	2526/18400				utcomes at a p <	
					-										1:0	CHF OR (95% CI)		the above or	
p value	0.54	0.19	0.79	0.85	0.29	0.65	0.81	0.34	0.46	0.02	0.32	0.23	0.40	0.60	6.0	CHF		ith any of	2.
95% CI F	(0.98, 1.04)	(0.95, 1.01)	0.97, 1.04)	0.96, 1.03)	0.96, 1.01)	(0.96, 1.02)	(0.97, 1.03)	(0.98, 1.06)	(0.98, 1.04)	(0.92, 0.99)	0.99, 1.05)	(0.95, 1.01)	0.96, 1.02)	(0.97, 1.05)				associated w	gures 1 and
Stroke OR	1.01	0.98	1.00 (1.00	0.98 () 66.0	1.00 (1.02 (1.01	0.96 ()	1.02	0.98 ()) 66.0	1.01 (were found	ions as in Fi
Cases/Controls	14779/67312	14779/67312	14779/67312	14779/67312	14779/67312	14779/67312	14779/67312	14779/67312	14779/67312	14779/67312	14779/67312	14779/67312	14779/67312	14779/67312	r=	6 CI)		Of the 14 urate-specific SNPs investigated in association with coronary heart disease, ischemic stroke, and heart failure (HF), none were found associated with any of the above outcomes at a p < 0.01. * Data presented from	10,347) (39). CHD = coronary heart disease; other abbreviations as in Figures 1 and 2.
			-	-			-		-			1			1:0	Ischemic Stroke OR (95% CI)		ke, and heart fa	heart disease;
p value	0.83	0.47	0.70	0.49	0.83	0.89	0.70	0.51	0.11	0.54 -	0.21	0.88	0.20	0.44	6.0	Ischerr		emic strol	coronary
95% CI	(0.97, 1.03)	(0.98, 1.04)	(0.96, 1.03)	(0.96, 1.02)	(0.97, 1.02)	(0.97, 1.02)	(0.97, 1.02)	(0.98, 1.05)	(1.00, 1.05)	(0.96, 1.02)	(0.95, 1.01)	(0.98, 1.03)	(0.96, 1.01)	(0.98, 1.04)				isease, ische	(6). CHD =
CHD OR	1.00	1.01	0.99	0.99	1.00	1.00	1.00	1.01	1.02	0.99	0.98	1.00	0.99	1.01				ry heart d	0,347) (3
Cases/Controls	39398/52707	43260/56244	41194/54454	44189/57955	45344/59110	44189/57955	45318/59085	44982/54538	36880/46828	42854/57062	35037/42222	52702/68275	54501/66914	44818/58585	۲Ħ			tion with corona	a serum urate genome-wide association study of 48 studies (n = 11
	-		-		-+-	-	•••	-			-+-				1	CAD OR (95% CI)		gated in associa	ation study of 4
A1(F1)/A2*	G(0.42)/A	T(0.35)/G	T(0.28)/C	G(0.69)/C	C(0.42)/A	T(0.44)/C	G(0.42)/T	G(0.16)/A	C(0.57)/T	A(0.18)/G	A(0.46)/C	T(0.27)/C	C(0.49)/T	A(0.77)/G	[0.0			SNPs investi	wide associa
Gene	STCI	ACVR1B-L1	PRKAG2	TMEM171	HLF	HNF4G	SFMBT1	NRXN2	TRIM46	A1CF	PDZK1	RREB1	SLC22A11	SLC2A9				e-specific	, genome-
SNP	rs17786744	rs7976059	rs10480300	rs17632159	rs7224610	rs2941484	rs6770152	rs478607	rs11264341	rs10821905	rs1471633	rs675209	rs2078267	rs12498742				Of the 14 urat	a serum urate

Type 2 Diabetes Coronary Heart Disease Ischemic Stroke	+		0.95	(0.86, 1.05)	0.28
	+				
Ischemic Stroke			1.02	(0.92, 1.12)	0.73
	+		0.99	(0.88, 1.12)	0.93
Heart Failure			1.07	(0.88, 1.30)	0.51
Gout	i		5.84	(4.56, 7.49)	4.2E-44
0.5	1.0	5.0 10.0			
OR per SD increase in	Serum Urate	Conferred by G	enetic Scor	e	
Keenan, T. et al. J Am Coll Carc	liol. 2016; 67	7(4):407-16.			

Our findings were consistent with a prior report that evaluated variation at the *SLC2A9* gene in association with ischemic heart disease that found no evidence of an association between genetically lowered uric acid and CHD or blood pressure (21). The current study extended these prior findings by evaluating all variants associated with uric acid systematically, exploring pleiotropy for all uric-acid related variants, investigating other cardiometabolic outcomes (i.e., T2DM, stroke, and HF), and assessing >7-fold more CHD cases (54,501 in the current report vs. 7,172 in the prior report). Thus, it provided an analysis adequately powered to assess urate variants and genetic scores known to have modest effects on urate levels.

We observed that one serum urate SNP in the ATXN2 gene, which was pleiotropic for major lipid, glycemic, and anthropometric traits (thus excluded from our score-based MR analysis), appeared to be associated with risks of CHD and ischemic stroke at nominal levels of significance. This SNP is located in a high-frequency (~40%) long-range (1.6 Mb) haplotype, previously described to be associated with a range of other traits including type 1 diabetes, celiac disease, and elevated platelet counts. This haplotype is speculated to have arisen from a selective sweep specific to Europeans ~3,400 years ago when highdensity human settlements were expanding in that region of the world (33). In analyses restricted to participants of South Asian ancestry, we did not find this variant to be associated with major lipids in 37,000 participants or with risks of CHD (9,000 cases and 9,000 controls) or ischemic stroke (3,500 cases and 5,000 controls). Because of the high pleiotropic nature of this locus and specificity to populations of European ancestry, it is unlikely that the ATXN2 locus leads to CHD by increasing serum urate levels. **STUDY LIMITATIONS.** Potential limitations of this study should be considered. First, while analyses on HF in the current study were underpowered (Online Table 9), the concordance of the null findings observed for all cardiometabolic outcomes tend to suggest a lack of a major etiological role of serum urate levels in HF. Second, we evaluated only 50 traits to assess pleiotropy for uric acid SNPs and did not conduct measurements for all possible biological traits; however, we conducted analyses using both single SNPs and a GRS in association with cardiometabolic outcomes. Importantly, we also conducted analyses for a variant, rs12498742, that imparts the strongest effect on uric acid levels (Online Table 10) and is located in an intron of the SLC2A9 gene that encodes for a glucose and urate transporter in the kidney, hence providing biological plausibility to our hypothesis. We did not find this variant to be associated with any other trait apart from circulating urate levels; hence enabling MR analyses using this variant only. We did not find rs12498742 to be associated with any cardiometabolic outcome despite the fact that MR analyses with this variant were sufficiently powered (Online Table 9).

Third, nonpleiotropic variants in addition to the SLC2A9 variant explained only 15.3% of the variance in serum urate levels (Online Table 10). However, none of them were associated with any of the investigated cardiometabolic endpoints in our large-scale analyses, casting further doubt on serum urate as a causal factor. Fourth, as suggested by our power calculations (Online Table 9), although we were able

to exclude effects imparted by a 1 SD change in serum urate levels on disease risk, which are weak to modest and consistent with prior epidemiological studies (3-11) (Online Table 9), our analyses may not have detected very weak disease risk estimates (e.g., OR for CHD < 1.10).

Fifth, while our assessment of causality was limited to SNPs that are observed to be nonpleiotropic, it can be argued that the loci that do exhibit pleiotropy can mediate the disease. We ruled out the latter possibility by demonstrating that risk scores comprised of all 28 SNPs or 14 pleiotropic SNPs were not associated with any cardiometabolic outcomes. Finally, although we had access to only summary-level data, preventing adjustment for factors acting as potential mediators between genotypes and disease risk, MR analyses on summary-level data have been shown to achieve results similar to the methods that have used individual participant data (14-19). Moreover, analyses with gout provided a positive control and reinforced the findings observed for other outcomes.

CONCLUSIONS

Our MR analyses did not support a causal role of circulating serum urate concentrations in cardiometabolic conditions. Our results suggested that lowering serum urate levels may not translate into risk reductions for T2DM, CHD, ischemic stroke, or HF events.

ACKNOWLEDGMENTS The authors would like to thank the CARDIOGRAM consortium, the C4D consortium, the CHARGE Heart Failure Consortium, the GUGC Consortium, and the METASTROKE consortium for contributing data. The PROMIS investigators also acknowledge the contributions made by the following: Mohammad Zeeshan Ozair, Usman Ahmed, Abdul Hakeem, Hamza Khalid, Kamran Shahid, Fahad Shuja, Ali Kazmi, Mustafa Qadir Hameed, Naeem Khan, Sadiq Khan, Ayaz Ali, Madad Ali, Saeed Ahmed, Muhammad Waqar Khan, Muhammad Razaq Khan, Abdul Ghafoor, Mir Alam, Riazuddin, Muhammad Irshad Javed, Abdul Ghaffar, Tanveer Baig Mirza, Muhammad Shahid, Jabir Furqan, Muhammad Iqbal Abbasi, Tanveer Abbas, Rana Zulfiqar, Muhammad Wajid, Irfan Ali, Muhammad Ikhlaq, Danish Sheikh, and Muhammad Imran.

For the CEDIR (Cerebrovascular Diseases Registry) (Milano, Italy), the authors would like to acknowledge: Eugenio A. Parati and Emilio Ciusani from Fondazione IRCCS Istituto Neurologico "Carlo Besta" of Milan, who contributed to collection and genotyping of cases within CEDIR (Cerebrovascular Diseases Registry), funded by Annual Research Funding of the Italian Ministry of Health (Grant Numbers: RC 2007/LR6, RC 2008/LR6; RC 2009/LR8; RC 2010/LR8). Simona Barlera and Maria Grazia Franzosi from Istituto di Ricerche Farmacologiche "Mario Negri" of Milan contributed to collection and genotyping of the PROCARDIS controls, funded by FP6 LSHM-CT-2007-037273.

REPRINT REQUESTS AND CORRESPONDENCE: Dr. Danish Saleheen, Department of Biostatistics and Epidemiology, University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, Pennsylvania 19104. E-mail: saleheen@mail.med.upenn.edu. OR Dr. Benjamin F. Voight, Department of Systems Pharma-cology and Translational Therapeutics and Department of Genetics, University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, Pennsylvania 19104. E-mail: bvoight@upenn.edu.

PERSPECTIVES

COMPETENCY IN MEDICAL KNOWLEDGE: Although elevated serum uric acid levels have been associated with an increased risk of cardiometabolic diseases, a causal link has not been established. The results of a large Mendelian randomization study suggest that lowering serum urate levels may not translate into reductions in the risks of type 2 diabetes, coronary heart disease, ischemic stroke, or heart failure.

TRANSLATIONAL OUTLOOK: Genetic studies that take advantage of the random assortment of alleles during meiosis can save time and resources, minimize bias, and inform clinical practice when data from prospective clinical trials are not available to provide evidence for causality.

REFERENCES

1. Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME. Febuxostat for treating chronic gout. Cochrane Database Syst Rev 2012;11:CD008653.

2. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008;359:1811-21.

3. Kodama S, Saito K, Yachi Y, et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care 2009;32:1737-42.

4. Wheeler JG, Juzwishin KD, Eiriksdottir G, et al. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. PLoS Med 2005;2:e76.

5. Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2010;62:170-80.

6. Chuang SY, Chen JH, Yeh WT, et al. Hyperuricemia and increased risk of ischemic heart disease in a large Chinese cohort. Int J Cardiol 2012;154: 316-21.

7. Kivity S, Kopel E, Maor E, et al. Association of serum uric acid and cardiovascular disease in healthy adults. Am J Cardiol 2013;111: 1146–51. **8.** Hozawa A, Folsom AR, Ibrahim H, et al. Serum uric acid and risk of ischemic stroke: the ARIC study. Atherosclerosis 2006;187:401-7.

9. Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum 2009;61: 885-92.

10. Holme I, Aastveit AH, Hammar N, et al. Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 men and women in the apolipoprotein MOrtality RISk study (AMORIS). J Intern Med 2009;266:558-70.

11. Krishnan E. Hyperuricemia and incident heart failure. Circ Heart Fail 2009;2:556-62.

12. Lawlor DA, Harbord RM, Sterne JA, et al. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med 2008;27:1133-63.

 Davey Smith G, Ebrahim S. What can Mendelian randomisation tell us about modifiable behavioural and environmental exposures? Br Med J 2005;330:1076-9.

14. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet 2012;380:572–80.

15. Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration, Sarwar N, Sandhu MS, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010;375: 1634–9.

16. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with lp(a) lipoprotein level and coronary disease. N Engl J Med 2009;361: 2518-28.

17. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009;301:2331-9.

18. Ken-Dror G, Humphries SE, Kumari M, et al. A genetic instrument for Mendelian randomization of fibrinogen. Eur J Epidemiol 2012;27:267-79.

19. Elliott P, Chambers JC, Zhang W, et al. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 2009;302: 37-48.

20. Pfister R, Barnes D, Luben R, et al. No evidence for a causal link between uric acid and type 2 diabetes: a Mendelian randomisation approach. Diabetologia 2011;54:2561-9.

21. Palmer TM, Nordestgaard BG, Benn M, et al. Association of plasma uric acid with ischaemic heart disease and blood pressure: Mendelian randomisation analysis of two large cohorts. BMJ 2013;347:f4262.

22. Stark K, Reinhard W, Grassl M, et al. Common polymorphisms influencing serum uric acid levels contribute to susceptibility to gout, but not to coronary artery disease. PLoS One 2009;4:e7729.

23. Yang Q, Kottgen A, Dehghan A, et al. Multiple genetic loci influence serum urate levels and their

relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet 2010;3:523-30.

24. Saleheen D, Zaidi M, Rasheed A, et al. The Pakistan Risk of Myocardial Infarction Study: a resource for the study of genetic, lifestyle and other determinants of myocardial infarction in south Asia. Eur J Epidemiol 2009;24:329–38.

25. 1000 Genomes Project Consortium, Abecasis GR, Altshuler D, et al. A map of human genome variation from population-scale sequencing. Nature 2010;467:1061-73.

26. Newton-Cheh C, Johnson T, Gateva V, et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet 2009;41:666-76.

27. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010;466:707-13.

28. Heid IM, Jackson AU, Randall JC, et al. Metaanalysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet 2010;42:949–60.

29. Lango Allen H, Estrada K, Lettre G, et al. Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature 2010;467:832-8.

30. Speliotes EK, Willer CJ, Berndt SI, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet 2010;42:937-48.

31. Dupuis J, Langenberg C, Prokopenko I, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 2010;42:105-16.

32. Saxena R, Hivert MF, Langenberg C, et al. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet 2010;42:142-8.

33. Soranzo N, Sanna S, Wheeler E, et al. Common variants at 10 genomic loci influence hemoglobin A(1)(C) levels via glycemic and nonglycemic pathways. Diabetes 2010;59:3229-39.

34. Strawbridge RJ, Dupuis J, Prokopenko I, et al. Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. Diabetes 2011;60: 2624-34.

35. Morris AP, Voight BF, Teslovich TM, et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet 2012;44:981-90.

36. The CARDIOGRAMplusC4D Consortium, Deloukas P, Kanoni S, Willenborg C, et al. Largescale association analysis identifies new risk loci for coronary artery disease. Nat Genet 2012;45: 25-33.

37. Traylor M, Farrall M, Holliday EG, et al. Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol 2012;11:951-62.

38. Smith NL, Felix JF, Morrison AC, et al. Association of genome-wide variation with the risk of incident heart failure in adults of European and African ancestry: a prospective meta-analysis from the cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium. Circ Cardiovasc Genet 2010;3:256-66.

39. Kottgen A, Albrecht E, Teumer A, et al. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet 2013;45:145-54.

40. Palmer TM, Lawlor DA, Harbord RM, et al. Using multiple genetic variants as instrumental variables for modifiable risk factors. Stat Methods Med Res 2012;21:223-42.

41. Johnson T. Efficient calculation for multi-SNP genetic risk scores. Poster presented at: American Society of Human Genetics Annual Meeting; November 7, 2012; San Francisco, California.

42. Dastani Z, Hivert MF, Timpson N, et al. Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multiethnic meta-analysis of 45,891 individuals. PLoS Genet 2012;8:e1002607.

43. Voight BF. MR_predictor: a simulation engine for Mendelian randomization studies. Bioinformatics 2014;30:3432-4.

44. Bhole V, de Vera M, Rahman MM, Krishnan E, Choi H. Epidemiology of gout in women: fifty-two-year followup of a prospective cohort. Arthritis Rheum 2010;62:1069-76.

45. Dziuba J, Alperin P, Racketa J, et al. Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes. Diabetes Obes Metab 2014;16:628-35.

46. Givertz MM, Mann DL, Lee KL, et al. Xanthine oxidase inhibition for hyperuricemic heart failure patients: design and rationale of the EXACT-HF study. Circ Heart Fail 2013;6:862-8.

47. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008;300:924–32.

48. George J, Carr E, Davies J, et al. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006;114: 2508-16.

49. Kelkar A, Kuo A, Frishman WH. Allopurinol as a cardiovascular drug. Cardiol Rev 2011;19:265-71.

50. Kim SC, Schneeweiss S, Choudhry N, et al. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study. Am J Med 2015;128:653.e7-16.

KEY WORDS genetic, pleiotropy, single nucleotide polymorphism

APPENDIX For supplemental text, tables, and figures, please see the online version of this article.